Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2018
Price :
$35
*
At a glance
- Drugs Milvexian (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 30 Nov 2017 Planned number of patients changed from 32 to 33.
- 30 Nov 2017 Status changed from recruiting to completed.
- 20 Sep 2017 Planned number of patients changed from 24 to 32.